Silence Therapeutics (SLN) vs. Its Peers Head-To-Head Review

Silence Therapeutics (NASDAQ:SLN – Get Free Report) is one of 842 public companies in the “Biotechnology” industry, but how does it contrast to its competitors? We will compare Silence Therapeutics to similar companies based on the strength of its dividends, analyst recommendations, valuation, earnings, risk, institutional ownership and profitability.

Institutional & Insider Ownership

98.7% of Silence Therapeutics shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 3.0% of Silence Therapeutics shares are owned by insiders. Comparatively, 13.2% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Silence Therapeutics and its competitors gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Silence Therapeutics $560,000.00 -$88.61 million -18.51
Silence Therapeutics Competitors $690.26 million $7.76 million -18.38

Silence Therapeutics’ competitors have higher revenue and earnings than Silence Therapeutics. Silence Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a summary of current ratings and target prices for Silence Therapeutics and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Silence Therapeutics 1 4 2 0 2.14
Silence Therapeutics Competitors 9920 15335 45741 1601 2.54

Silence Therapeutics currently has a consensus price target of $24.00, indicating a potential upside of 21.15%. As a group, “Biotechnology” companies have a potential upside of 110.28%. Given Silence Therapeutics’ competitors stronger consensus rating and higher possible upside, analysts plainly believe Silence Therapeutics has less favorable growth aspects than its competitors.

Profitability

This table compares Silence Therapeutics and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Silence Therapeutics -8,943.86% -56.32% -32.42%
Silence Therapeutics Competitors -12,516.26% -215.37% -31.41%

Risk and Volatility

Silence Therapeutics has a beta of 1.34, suggesting that its share price is 34% more volatile than the S&P 500. Comparatively, Silence Therapeutics’ competitors have a beta of -1.85, suggesting that their average share price is 285% less volatile than the S&P 500.

Summary

Silence Therapeutics competitors beat Silence Therapeutics on 9 of the 13 factors compared.

Silence Therapeutics Company Profile

(Get Free Report)

Silence Therapeutics is a biotechnology company developing medicines based on RNA interference (RNAi), a biological process that can reduce production of specific disease-related proteins. Its proprietary mRNAi GOLD platform is designed to create small interfering RNA (siRNA) medicines, including treatments that target genes expressed in the liver. The company’s research and development programs have included zerlasiran, which targets lipoprotein(a), a risk factor for cardiovascular disease, and divesiran, investigated for blood disorders.

Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.